GO
Loading...

Enter multiple symbols separated by commas

Novartis Drug for Osteoporosis Shows Promising Results: Study

A new study offers the millions of people who have osteoporosis the hope of taking a drug to treat it only once a year.

The New England Journal of Medicine reports that patients who got a once-a-year infusion of the Novartis drug Reclast saw a 70% reduction in the risk of spinal fractures and a 40% drop in the risk of hip fractures.

An editorial in the peer-reviewed medical journal calls the results "impressive".

Novartis hopes to win FDA approval of Reclast for post-menopausal osteoporosis by the end of this year.

It would compete in a multi-billion dollar drug segment with Roche's Boniva, Merck's Fosamax and Actonel from Sanofi-Aventis and Procter & Gamble. But many patients go off those drugs because they're cumbersome to take.

Researchers saw an abnormal heart rhythm in some Reclast patients. Novartis paid for the study.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • KLM landing

    A Dutch storm violently rocked a plane as it approached for a landing, narrowly avoiding a crash on the runway.

  • Treasure hunters have found a trove of 300-year-old gold coins off the coast of Florida worth more than $1 million, NBC affiliate WESH reported.

  • Donald Trump

    Trump himself gave one of the clearest examples yet of why his candidacy is doomed to fail, and why the debate stage could be his Waterloo.

U.S. Video

  • Opening Bell, July 28, 2015

    Shark Tank's Kevin O'Leary celebrates the recent launch of the O'Shares FTSE U.S. quality dividend ETF at the NYSE and Bed, Bath, & Beyond at the Nasdaq.

  • Looking ahead to Twitter's earnings report

    CNBC's Morgan Brennan and PCMag.com Editor-in-Chief Dan Costa discuss the main points that investors should be looking out for during Twitter's earnings call after the closing bell.

  • Cramer: Hats off to China

    CNBC's Jim Cramer weighs in on China's markets, Pfizer's earnings and UPS.